Skip to main content

Table 1 Clinical and molecular features of cancer cohorts

From: Methylation and expression of the tumour suppressor, PRDM5, in colorectal cancer and polyp subgroups

 

BRAFmutant

BRAFwild type

P value

N

214

122

-

Average Age (years)

74.1

67.1

<0.0001

Gender - female

139/214 (65.0%)

49/122 (40.2%)

<0.0001

Tumour Location (Proximal)

164/192 (85.4%)

28/117 (23.9%)

<0.0001

AJCC stage I/II

110/170 (64.7%)

58/111 (52.3%)

<0.05

AJCC stage III/IV

60/170 (35.3%)

53/111 (47.7%)

Mucinous

37/96 (38.5%)

3/42 (7.1%)

<0.0001

Differentiation (poor)

38/96 (39.6%)

12/42 (28.6%)

0.2

MSI High

120/214 (56.1%)

0

-

CIMP High

154/205 (75.1%)

3/121 (2.5%)

<0.0001

p53 Mutation

29/107 (27.1%)

40/80 (50.0%)

0.002

KRAS Mutation

0

38/80 (47.5%)

-

PRDM5 Methylation

77/214 (36.0%)

4/122 (3.3%)

<0.0001

PRDM5 PMR

27

3

<0.0001

Nuclear Beta-Catenin

36/92 (39.1%)

36/42 (85.7%)

<0.0001

  1. Significant p values indicated in bold text.